EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ascletis Pharma's enterprise value is HK$-1,366.89 Mil.
Ascletis Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$61.90 Mil. Therefore, Ascletis Pharma's EV-to-Revenue for today is -22.08.
The historical rank and industry rank for Ascletis Pharma's EV-to-Revenue or its related term are showing as below:
HKSE:01672'
s EV-to-Revenue Range Over the Past 10 Years
Min: -19.53 Med: -0.36 Max: 183.71
Current: -21.85
During the past 8 years, the highest EV-to-Revenue of Ascletis Pharma was 183.71. The lowest was -19.53. And the median was -0.36.
HKSE:01672's EV-to-Revenue is ranked better than 98.07% of 1038
companies
in the Biotechnology industry
Industry Median: 7.985
vs HKSE:01672: -21.85
As of today (2024-06-05), Ascletis Pharma's stock price is HK$1.14.
Ascletis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.06. Therefore, Ascletis Pharma's PS Ratio for today is 20.00.
Ascletis Pharma EV-to-Revenue Historical Data
The historical data trend for Ascletis Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ascletis Pharma's EV-to-Revenue
For the Biotechnology subindustry, Ascletis Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's EV-to-Revenue falls into.
Ascletis Pharma's current Enterprise Value is HK$-1,366.89 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$61.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma's share price for today is HK$1.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ascletis Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01672 has been successfully added to your 